ctDNA/MRD Testing for Colon Cancer: A Work in Progress or Ready for Prime-Time Standard of Care?
J Natl Compr Canc Netw. 2024.
PMID: 39681074
Review.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2022 | 1 |
| 2024 | 3 |
| 2025 | 1 |
Search Results
24 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Did you mean
ctDNA/MRD testing for colon cancer: at work in progress or ready for prime time standard of care?
(26 results)?
ctDNA/MRD Testing for Colon Cancer: A Work in Progress or Ready for Prime-Time Standard of Care?
J Natl Compr Canc Netw. 2024 Dec;22(10):e247049. doi: 10.6004/jnccn.2024.7049.
J Natl Compr Canc Netw. 2024.
PMID: 39681074
Review.
In patients with surgically resectable colon cancer (CC), clinicopathologic characteristics translate into cancer staging and predict recurrence risk. ...Recent clinical trials show promise for using ctDNA to guide therapy, in particular standard-risk …
In patients with surgically resectable colon cancer (CC), clinicopathologic characteristics translate into cancer stagi …
Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?
Ther Adv Med Oncol. 2022 Dec 18;14:17588359221143975. doi: 10.1177/17588359221143975. eCollection 2022.
Ther Adv Med Oncol. 2022.
PMID: 36570410
Free PMC article.
Review.
With this background in place, we next review the best available evidence for the use of ctDNA in early-stage colon cancer. Observational cohorts have established MRD after surgery as a significant prognostic factor for recurrence in stage II and III colon …
With this background in place, we next review the best available evidence for the use of ctDNA in early-stage colon cancer. Ob …
Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
Eur Urol. 2019 Nov;76(5):543-545. doi: 10.1016/j.eururo.2019.06.014. Epub 2019 Jun 25.
Eur Urol. 2019.
PMID: 31248604
Free PMC article.
Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor in metastatic hormone-sensitive prostate cancer (mHSPC). However, there is currently not enough evidence to recommend RT to the prim …
Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor …
Imaging of the colon in inflammatory bowel disease: ready for prime time?
Curr Drug Targets. 2012 Sep 1;13(10):1252-60. doi: 10.2174/138945012802429714.
Curr Drug Targets. 2012.
PMID: 22664082
Review.
Endoscopy is currently considered the reference standard for the evaluation of disease activity and severity in patients with inflammatory bowel disease (IBD). ...Overall, MRI findings accurately reflect disease activity and provide reliable informatio …
Endoscopy is currently considered the reference standard for the evaluation of disease activity and severity in patients with …
Microaxial mechanical circulatory support in cardiogenic shock: ready for prime time?
Br J Anaesth. 2025 May;134(5):1290-1294. doi: 10.1016/j.bja.2025.02.010. Epub 2025 Apr 2.
Br J Anaesth. 2025.
PMID: 40180803
Randomised controlled studies on the use of intra-aortic balloon counterpulsation and veno-arterial extracorporeal life support have failed to offer a survival benefit compared with standard therapy in patients with myocardial infarction-associated cardiogenic shock. Thus, …
Randomised controlled studies on the use of intra-aortic balloon counterpulsation and veno-arterial extracorporeal life support have failed …
Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
Cancers (Basel). 2020 May 13;12(5):1223. doi: 10.3390/cancers12051223.
Cancers (Basel). 2020.
PMID: 32414145
Free PMC article.
Review.
The current standard of care for smoldering multiple myeloma (SMM) is observation until there is end-organ involvement. With newer and more effective treatments available, a question that is increasingly asked is whether early intervention in patients with SM …
The current standard of care for smoldering multiple myeloma (SMM) is observation until there is end-organ involvement. …
CAR T-Cells in Multiple Myeloma Are Ready for Prime Time.
J Clin Med. 2020 Nov 6;9(11):3577. doi: 10.3390/jcm9113577.
J Clin Med. 2020.
PMID: 33172026
Free PMC article.
Review.
Nevertheless, still, a major proportion of MM patients will relapse, underscoring the need for new therapies in this disease. Moreover, survival in patients failing the current standard of care regimens (including PI, IMIDs, and anti-CD38 MoAb), which …
Nevertheless, still, a major proportion of MM patients will relapse, underscoring the need for new therapies in this disease. Moreove …
Autonomic Modulation in Heart Failure: Ready for Prime Time?
Curr Cardiol Rep. 2015 Nov;17(11):103. doi: 10.1007/s11886-015-0652-2.
Curr Cardiol Rep. 2015.
PMID: 26384110
Review.
While therapies that block over-activity of the sympathetic nervous system are now standard of care, much less well studied are therapies aimed at augmenting the parasympathetic nervous system. ...
While therapies that block over-activity of the sympathetic nervous system are now standard of care, much less well stu …
Are Seizure Detection Devices Ready for Prime Time?
Epilepsy Curr. 2019 Jan;19(1):36-37. doi: 10.1177/1535759719827430. Epub 2019 Feb 15.
Epilepsy Curr. 2019.
PMID: 30838924
Free PMC article.
Standards for testing and clinical validation of seizure detection Beniczky S, Ryvlin P. Epilepsia. 2018;59(S1):9-13. https://doi.org/10.1111/epi.14049 To increase the quality of studies on seizure detection devices, we propose standards for testing and clinical val …
Standards for testing and clinical validation of seizure detection Beniczky S, Ryvlin P. Epilepsia. 2018;59(S1):9-13. https://doi.org …
Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.
Eur J Cancer. 2020 Dec;141:9-20. doi: 10.1016/j.ejca.2020.09.007. Epub 2020 Oct 23.
Eur J Cancer. 2020.
PMID: 33125947
Free article.
Review.
CONCLUSION: Pre-therapeutic genotyping of UGT1A1 in patients initiating treatment with irinotecan improves patient safety, is likely to be cost-saving, and should, therefore, become standard of care....
CONCLUSION: Pre-therapeutic genotyping of UGT1A1 in patients initiating treatment with irinotecan improves patient safety, is likely to be c …
Cite